发明公开
EP1759326A2 MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY
审中-公开
稳定同位素MARK IN体内测分子速度流经CRITICAL方式的生物标记药物作用与疾病活动
- 专利标题： MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY
- 专利标题（中）： 稳定同位素MARK IN体内测分子速度流经CRITICAL方式的生物标记药物作用与疾病活动
-
申请号： EP05733311.4申请日： 2005-02-22
-
公开(公告)号： EP1759326A2公开(公告)日： 2007-03-07
- 发明人: HELLERSTEIN, Marc, K.
- 申请人： The Regents of the University of California
- 申请人地址： 12th Floor, 1111 Franklin Street Oakland, California 94607-5200 US
- 专利权人： The Regents of the University of California
- 当前专利权人： The Regents of the University of California
- 当前专利权人地址： 12th Floor, 1111 Franklin Street Oakland, California 94607-5200 US
- 代理机构： Holmberg, Martin Tor
- 优先权： US546580P 20040220; US581028P 20040617
- 国际公布： WO2005081943 20050909
- 主分类号： G06G7/48
- IPC分类号： G06G7/48
摘要：
The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through metabolic pathways of interest.
信息查询
